Aetna modified CPB 0626 for hematopoietic cell transplantation covering thalassemia major and sickle cell anemia, effective October 8, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0626, which governs allogeneic hematopoietic cell transplantation (HCT) for thalassemia major and sickle cell anemia. This Aetna hematopoietic cell transplantation coverage policy directly affects billing for CPT codes 38204, 38205, 38207, 38208, 38209, 38230, and 38240, along with HCPCS code S2150. If your team bills for stem cell transplant services, this change requires a close read — the criteria for medical necessity are specific, and the exclusions carry real denial risk.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia |
| Policy Code | CPB 0626 |
| Change Type | Modified |
| Effective Date | October 8, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Transplant Medicine, Pediatrics |
| Key Action | Audit prior authorization documentation and confirm donor HLA-match status is captured before billing CPT 38240 or 38205 |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
The CPB 0626 Aetna system defines two separate coverage tracks — one for thalassemia major, one for sickle cell anemia. They look similar but carry different criteria. Don't conflate them.
Thalassemia Major (homozygous beta-thalassemia)
Aetna covers allogeneic HCT for thalassemia major in children or young adults up to age 45. The member must meet the transplanting institution's written eligibility criteria. If the transplanting institution has no written criteria on file, Aetna falls back to a single requirement: the member must have a haploidentical to HLA-matched donor.
That fallback is actually simpler than it sounds. But "simpler" doesn't mean easy to document. Make sure your transplant center's written eligibility criteria are clearly referenced in the authorization request. If they don't have formal written criteria, document the donor match status explicitly.
Sickle Cell Anemia
The sickle cell anemia track adds a layer. Coverage applies to children or young adults when the member meets the transplanting institution's written eligibility criteria — same starting point as thalassemia. But the fallback criteria here are stricter. Without institutional written criteria, both of the following must be met:
| # | Covered Indication |
|---|---|
| 1 | The member has a haploidentical to HLA-matched donor |
| 2 | The member has a history of stroke, is at increased risk of stroke, or has documented end-organ damage |
Aetna defines increased risk specifically. Recurrent acute chest syndrome, recurrent vaso-occlusive crises, and red blood cell alloimmunization on chronic transfusion therapy all qualify. These aren't vague — document whichever applies, because claim denial on sickle cell HCT cases almost always comes down to missing clinical evidence on stroke risk or end-organ damage.
The Age 45 Cutoff
Any request for allogeneic HCT — for either diagnosis — in adults older than 45 goes to Aetna's National Medical Excellence (NME) unit for review. This is not a standard prior authorization path. If your patient is 46 and your team submits through the normal PA channel, expect delays or outright denial. Route these cases to NME from the start.
The coverage policy does not explicitly state prior authorization is required, but given the complexity and cost of HCT, your team should assume prior authorization is needed and initiate it well before the procedure date. Check plan-specific requirements for each member.
Aetna HCT Exclusions and Non-Covered Indications
Three categories are explicitly experimental, investigational, or unproven under this coverage policy. All three carry real billing risk if your team doesn't flag them early.
Autologous HCT for thalassemia major or sickle cell anemia. Aetna will not cover autologous transplant for either diagnosis in children or young adults. Insufficient peer-reviewed evidence is the stated reason. CPT codes 38206 (autologous blood-derived harvesting), 38232 (autologous bone marrow harvesting), and 38241 (autologous HPC transplantation) are not covered for these indications. CPT 38210 (specific cell depletion, T-cell) is also excluded. Don't bill these expecting reimbursement — you won't get it.
T-lymphocyte subsets at engraftment. Using T-cell subset testing to predict acute graft-versus-host disease risk in thalassemia major patients is experimental. CPT 86359 (T cells, total count) and CPT 86360 (T cells, absolute CD4 and CD8 count with ratio) are not covered under this policy for that indication. If your institution does this routinely, flag it in your charge capture review.
Treosulfan-based T-cell depleted haploidentical stem cell transplantation. This protocol is experimental for both sickle cell disease and transfusion-dependent thalassemia. No specific CPT code is called out in the "not covered" list for this one, but the clinical protocol determines billing — if the transplant uses this approach, expect a coverage challenge.
Coverage Indications at a Glance
| Indication | Patient Age | Status | Relevant Codes | Notes |
|---|---|---|---|---|
| Thalassemia major — meets institutional criteria | Up to 45 | Covered | 38204, 38205, 38207, 38208, 38209, 38230, 38240, S2150 | Must reference institution's written eligibility criteria |
| Thalassemia major — no institutional criteria | Up to 45 | Covered | 38204, 38205, 38207, 38208, 38209, 38230, 38240, S2150 | Requires haploidentical to HLA-matched donor |
| Thalassemia major — any diagnosis | Over 45 | NME Review | 38240 | Route to National Medical Excellence unit |
| Sickle cell anemia — meets institutional criteria | Up to 45 | Covered | 38204, 38205, 38207, 38208, 38209, 38230, 38240, S2150 | Must reference institution's written eligibility criteria |
| Sickle cell anemia — no institutional criteria | Up to 45 | Covered | 38204, 38205, 38207, 38208, 38209, 38230, 38240, S2150 | Requires HLA-matched donor AND stroke history/risk or end-organ damage |
| Sickle cell anemia — any diagnosis | Over 45 | NME Review | 38240 | Route to National Medical Excellence unit |
| Autologous HCT — either diagnosis | Any | Not Covered | 38206, 38232, 38241 | Experimental — insufficient evidence |
| T-lymphocyte subset testing at engraftment | Any | Not Covered | 86359, 86360 | Experimental for GVHD risk prediction in thalassemia major |
| Treosulfan-based T-cell depleted haplo-identical SCT | Any | Not Covered | 38210 | Experimental for SCD and transfusion-dependent thalassemia |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
The real issue here is documentation timing. HCT cases take weeks to coordinate, and the authorization window often closes before clinical teams have pulled together everything Aetna needs. Don't let that happen on cases affected by this October 8, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for autologous HCT codes immediately. Remove CPT 38206, 38232, and 38241 from any thalassemia major or sickle cell anemia order sets or charge capture templates. These codes will not produce reimbursement under this policy. Catching this now prevents write-offs later. |
| 2 | Confirm transplanting institution eligibility criteria are documented before submitting prior authorization. If the institution has written criteria, attach them to the PA request. If they don't, document the donor HLA-match status clearly. This is Aetna's fallback — and it's your defense against claim denial. |
| 3 | For sickle cell anemia cases without institutional criteria, build a documentation checklist. You need the donor match AND one of these: stroke history, increased stroke risk (recurrent acute chest syndrome, recurrent vaso-occlusive crises, or red blood cell alloimmunization on chronic transfusion therapy), or documented end-organ damage. Get this from the clinical team before the PA goes out — not after a denial. |
| 4 | Flag all patients over age 45 for NME routing. This is not a standard PA workflow. Work with your authorization team to create a hard stop in your PA process for any HCT request where the patient is 46 or older. Missing this step wastes time and delays care. |
| 5 | Remove CPT 86359 and 86360 from T-cell monitoring protocols for thalassemia major patients in the transplant setting. If your institution runs T-lymphocyte subsets at engraftment to predict GVHD risk, those charges will not clear under CPB 0626. Talk to your transplant program's medical director about how to handle this clinically and financially. |
| 6 | Review your HLA typing billing for completeness. CPT codes 86813, 86817, 86821, and 86822 are related codes under this policy. Make sure these are captured and billed correctly alongside transplant procedures — they support medical necessity documentation. |
| 7 | If you're billing the treosulfan-based T-cell depleted haploidentical protocol, consult your compliance officer before October 8, 2025. This is a newer transplant approach and Aetna's experimental designation means any claims using this protocol for SCD or thalassemia will likely be denied. Your compliance officer and billing consultant need to weigh in on how to handle cases already in progress. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0626
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38204 | CPT | Management of recipient hematopoietic progenitor cell donor search and cell acquisition |
| 38205 | CPT | Blood-derived hematopoietic cell harvesting for transplantation, per collection; allogeneic |
| 38207 | CPT | Bone marrow or stem cell services/procedures |
| 38208 | CPT | Bone marrow or stem cell services/procedures |
| 38209 | CPT | Bone marrow or stem cell services/procedures |
| 38230 | CPT | Bone marrow harvesting for transplantation |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 38206 | CPT | Blood-derived hematopoietic cell harvesting; autologous | Not covered — autologous HCT is experimental for these diagnoses |
| 38210 | CPT | Transplant preparation; specific cell depletion within harvest, T-cell | Not covered — treosulfan-based T-cell depleted haploidentical SCT is experimental |
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous | Not covered — autologous HCT is experimental for these diagnoses |
| 38241 | CPT | Hematopoietic progenitor cell (HPC); autologous transplantation | Not covered — autologous HCT is experimental for these diagnoses |
| 86359 | CPT | T cells; total count | Not covered — T-lymphocyte subset testing at engraftment for GVHD prediction is experimental |
| 86360 | CPT | T cells; absolute CD4 and CD8 count, including ratio | Not covered — T-lymphocyte subset testing at engraftment for GVHD prediction is experimental |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvested and transplanted |
Key ICD-10-CM Diagnosis Codes
The policy document does not list specific ICD-10-CM codes. Work with your coding team to apply the appropriate diagnosis codes for thalassemia major (homozygous beta-thalassemia) and sickle cell anemia from your facility's code set.
Get the Full Picture for CPT 38240
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.